肥胖降低细胞因子靶向药而非细胞靶向药在类风湿关节炎中的真实世界疗效
肥胖对女性使用csDMARDs、TNF抑制剂、托珠单抗及男性使用托珠单抗的DAS28-ESR改善均有负向影响,但对利妥昔单抗和阿巴西普未见负向影响。
要点
- 肥胖降低TNF抑制剂和托珠单抗的DAS28-ESR改善,女性影响更广。
- 利妥昔单抗和阿巴西普的疗效未受肥胖负向影响。
- 女性使用csDMARDs时肥胖亦与DAS28-ESR改善降低相关。
核心结论
- 肥胖对细胞因子靶向治疗的真实世界疗效有负向影响,对细胞靶向治疗无负向影响。
- 肥胖对女性疗效的影响涉及更多结局和药物,对男性影响较少。
研究设计与样本
- 采用回归分析研究肥胖对药物疗效的影响,并校正潜在混杂因素。
主要发现
- 女性使用csDMARDs时,肥胖对DAS28-ESR改善的效应值为-0.15(95% CI: -0.26; -0.04)。
- 女性使用TNF抑制剂时,肥胖对DAS28-ESR改善的效应值为-0.22(95% CI: -0.31; -0.12)。
- 女性使用托珠单抗时,肥胖对DAS28-ESR改善的效应值为-0.22(95% CI: -0.42; -0.03)。
- 男性使用托珠单抗时,肥胖对DAS28-ESR改善的效应值为-0.41(95% CI: -0.74; -0.07)。
- 总体上未发现肥胖对利妥昔单抗和阿巴西普疗效的负向影响。
临床怎么用
- 对肥胖RA患者选择细胞因子靶向药时需考虑疗效可能降低。
- 肥胖RA患者可优先考虑细胞靶向药如利妥昔单抗或阿巴西普。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The effectiveness of TNF inhibitors in RA has been shown to be affected by obesity. No such effect has been found for abatacept and rituximab, while for tocilizumab results are ambiguous. Additionally, it remains unresolved whether sex is an effect modifier for obesity. We investigated the impact of obesity on the drug effectiveness of conventional synthetic or biologic DMARDs, taking into account potential sex-specific differences. METHODS: Data from 10 593 RA patients included in the German observational cohort study Rheumatoid Arthritis: oBservation of BIologic Therapy (RABBIT) since 2009 were analysed. Patients had to have a BMI ≥18.5 kg/m2, at least one follow-up and 6 months of observation time. The influence of obesity on drug effectiveness was investigated by regression analysis, adjusting for potential confounders. RESULTS: Obesity had a negative impact on improvement in the DAS with 28 joints using ESR as an inflammation marker of -0.15 (95% CI: -0.26; -0.04) units for women receiving conventional synthetic DMARDs, -0.22 (95% CI: -0.31; -0.12) units for women receiving TNF inhibitors, -0.22 (95% CI: -0.42; -0.03) units for women receiving tocilizumab and -0.41 (95% CI: -0.74; -0.07) units for men receiving tocilizumab. Overall, no negative obesity effects on the effectiveness of rituximab and abatacept were found. CONCLUSION: Obesity has a negative impact on the effectiveness of cytokine-targeted but not cell-targeted therapies in daily practice, affecting more outcomes and therapies in women than in men. Overall, no effects of obesity on treatment effectiveness were found for rituximab and abatacept.
引用
- Schäfer M, Meißner Y, Kekow J, et al. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 31745566. doi:10.1093/rheumatology/kez535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。